Enveric Biosciences (STU:SLZ0) EBITDA Margin %: 0.00% (As of Mar. 2026)


STU:SLZ0 Enveric Biosciences Inc STU:SLZ0
26 GF Score
Price €55.89
! 1 Warning Sign
View Full Analysis

What is Enveric Biosciences EBITDA Margin %?

Enveric Biosciences STU:SLZ0 26 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:SLZ0 with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Enveric Biosciences ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Enveric Biosciences's EBITDA for the three months ended in Mar. 2026 was €-1.38 Mil. Enveric Biosciences's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Enveric Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Enveric Biosciences  (STU:SLZ0) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Enveric Biosciences EBITDA Margin % Related Terms

Enveric Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Enveric Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences EBITDA Margin % Chart

Enveric Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Enveric Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:SLZ0 vs ACXP, CELZ, APM: EBITDA Margin % Comparison

For the Biotechnology subindustry, Enveric Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enveric Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's EBITDA Margin % falls into.


STU:SLZ0
26GF Score
Enveric Biosciences Inc STU:SLZ0
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enveric Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Enveric Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-7.322/0
= %

Enveric Biosciences's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.381/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Enveric Biosciences (STU:SLZ0) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Enveric Biosciences and its competitors. According to the industry distribution chart, Enveric Biosciences ranks #999999 out of 944 companies in the Biotechnology industry.
Is Enveric Biosciences' EBITDA Margin % too high?
Enveric Biosciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, Enveric Biosciences ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Enveric Biosciences has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' EBITDA Margin % compare to ACXP and CELZ?
According to the Biotechnology industry distribution chart, Enveric Biosciences ranks #999999 out of 944 companies for EBITDA Margin %. This places Enveric Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Enveric Biosciences and its competitors. Enveric Biosciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (STU:SLZ0) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Enveric Biosciences' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Enveric Biosciences (STU:SLZ0), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enveric Biosciences Business Description

Other Exchanges ENVB:USA
Address 245 First Street, 18th Floor, Riverview II, Cambridge, MA, USA, 02142
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
26GF Score

Get the complete analysis for STU:SLZ0

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.89
Price